36 results about "Refractory epilepsy" patented technology

A system of controlling distribution of a medication in the treatment or prevention of epilepsy is provided. A central controller of the system has a data store and one or more processors for reading and writing data to the data store. The data store comprises a database of patient records, each patient record having a medication authorization field. The central controller can output an authorization of a first prescription of epilepsy medication to a patient in dependence upon genetic test results for the patient and schedules a subsequent test for the patient prior to authorization of a subsequent prescription of epilepsy medication. Also provided are methods in which the subject systems find use. The systems and methods find use in the treatment of severe subtypes of epilepsy or refractory epilepsy, such as Dravet Syndrome.

A method of identifying an epileptogenic zone of a subject's brain includes receiving a plurality of electrical signals from a corresponding plurality of surgically implanted electrodes, calculating a first plurality of connectivities between each pair of electrodes based on a portion of each of the plurality of electrical signals corresponding to a first time period, assigning a rank corresponding to each electrode for the first period of time based on the first plurality of connectivities to provide a first plurality of ranks, calculating a second plurality of connectivities between each pair of electrodes based on a portion of each of the plurality of electrical signals corresponding to a second time period, assigning a rank corresponding to each electrode for the second period of time based on the second plurality of connectivities to provide a second plurality of ranks, identifying a cluster of electrodes among the plurality of electrodes based on relative changes between the first plurality of ranks from the first time period and the second plurality of ranks at the second time period, and identifying the epileptogenic zone based on the cluster of electrodes.

The present invention describes an oral pharmaceutical composition containing cannabinoid(s), an oily liquid solvent and a co-solvent, and a method for preparing and using same for the treatment of neurological disorders, especially refractory epilepsy. The analytical methods used to ensure the authenticity, quality and purity of the active pharmaceutical input and of the formulation produced werevalidated and have defined specifications.

A method for analyzing heart rate variability, and an apparatus and use thereof, the method for analyzing heart rate variability including collecting ECG data in vitro; digitizing and denoising the ECG data; forming the processed ECG data into a sinus NN interval sequence; selecting sinus NN interval data of 4 hours in an awake state; performing MSE calculation on the sinus NN interval sequence of 4 hours in an awake state; and extracting parameters representing the complexity of a heart rate by using MSE curves. The present invention may provide accurate and efficient screening for drug-refractory epilepsy patients who are suitable for vagus nerve stimulation surgery, thus avoiding unnecessary expenses, and avoiding missing the most opportune moment for treatment. At the same time, patients suitable for VNS surgery are selected by using MSE complexity feature parameters of ECG, thus improving the overall efficacy of VNS therapy.

The invention discloses the application of ethambutol or a pharmaceutically acceptable salt thereof as an active ingredient in the preparation of a drug for treating intractable epilepsy, and belongs to the technical field of medicine. Because the dosage of ethambutol hydrochloride is low, the toxic and side effects must be reduced, thereby reducing the toxic and side effects of the patient's medication. The new anti-refractory epilepsy drug has very significant social and economic significance.

The invention discloses a scorpion venom heat-resistant synthetic peptide and its application, belonging to the field of polypeptide drug research and development. The polypeptide of the present invention is the amino acid sequence of the scorpion venom heat-resistant peptide (SVHRP) detected from the venom of the traditional Chinese medicine East Asian scorpion scorpion (BmK). A sample of the heat-resistant peptide extract from scorpion venom with pharmacodynamic activity of Alzheimer's disease (premature Alzheimer's disease) was separated by LaGM composite material and repeated rapid magnetic separation, and then performed parallel mass spectrometry using nanoliter reversed-phase chromatography-electrospray mass spectrometry (nanoLC-ESI-MS). A polypeptide sequence consisting of 15 amino acid residues was detected in the experiment; a heat-resistant synthetic peptide of scorpion venom was prepared through solid-phase chemical synthesis, chromatographic purification and mass spectrometry identification. Its amino acid sequence is shown in SEQIDNo 1, which maintains the The pharmacodynamic activity and safety of the scorpion venom heat-resistant peptide, and the bioactivity of the scorpion venom heat-resistant peptide also promotes the reverse differentiation of glial cells into neural stem cells.